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Abstract
Neurogenesis is a life long process, but the rate of cell proliferation and differentiation decreases with age. In Alzheimer’s
patients, along with age, the presence of Ab in the brain inhibits this process by reducing stem cell proliferation and cell
differentiation. GLP-1 is a growth factor that has neuroprotective properties. GLP1 receptors are present on neuronal
progenitor cells, and the GLP-1 analogue liraglutide has been shown to increase cell proliferation in an Alzheimer’s disease
(AD) mouse model. Here we investigated acute and chronic effects of liraglutide on progenitor cell proliferation, neuroblast
differentiation and their subsequent differentiation into neurons in wild type and APP/PS-1 mice at different ages. APP/PS1
and their littermate controls, aged 3, 6, 12, 15 months were injected acutely or chronically with 25 nmol/kg liraglutide.
Acute treatment with liraglutide showed an increase in cell proliferation in APP/PS1 mice, but not in controls whereas
chronic treatment increased cell proliferation at all ages (BrdU and Ki67 markers). Moreover, numbers of immature neurons
(DCX) were increased in both acute and chronic treated animals at all ages. Most newly generated cells differentiated into
mature neurons (NeuN marker). A significant increase was observed with chronically treated 6, 12, 15 month APP/PS1 and
WT groups. These results demonstrate that liraglutide, which is currently on the market as a treatment for type 2 diabetes
(VictozaTM), increases neurogenesis, which may have beneficial effects in neurodegenerative disorders like AD.
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Adult neurogenesis is a process of continuous generation of new
neurons and glia cells from neuronal progenitor/stem cell (NSC),
which incorporates in existing circuitry [1]. Neurogenesis in the
mammalian brain arises from the subventricular zone (SVZ) in the
lateral ventricles, and the subgranular zone (SGZ) in the
hippocampal dentate gyrus [2–4]. Adult neurogenesis is believed
to be associated with memory, learning and the facilitation of long
term potentiation of synaptic transmission [5]. Factors regulating
adult neurogenesis include stress, age, inflammation processes and
drugs [6–9]. A decrease in hippocampal neurogenesis is a natural
ageing process [10,11], which is exacerbated in pathological
conditions like Parkinson’s and Alzheimer’s disease AD [12,13].
There is the potential that the normalisation of stem cell
proliferation in the brain may be of benefit in treating
neurodegenerative diseases, and therefore, this area of research
has been a focus point [14–17].
In AD, proliferation of NSCs, differentiation and neuronal
survival are adversely affected [18], and this is linked to the
accumulation of amyloid plaques [19] and the induction of
chronic inflammation [20,21]. Growth factors such as insulin
activate stem cell proliferation [22], and recently, it has been found
that insulin signaling in the brains of AD patients is desensitised
[23–25]. Impaired insulin signalling furthermore has clear
detrimental effects on cognition and on amyloid production
[26,27]. Pharmacological stimulation to increase proliferation of
endogenous NSC and their subsequent differentiation to new
neurons might serve as therapeutics for central nervous system
disorders with neurodegeneration as common characteristic
feature.
Glucagon like peptide -1 (GLP-1) is an endogenous incretin
hormone of 30-amino acid produced by the intestinal L cells [28].
Liraglutide (VictozaH), a GLP-1 analogue with an extended half-
life is used in type 2 diabetes treatment [29]. Subcutaneous
injections of liraglutide in humans are well tolerated without
affecting blood glucose levels in normoglycemic individuals [30].
Liraglutide displays glucoregulatory affects, facilitates insulin
secretion during periods of hyper-glycaemia and increases beta cell
mass [29,31]. GLP-1R is expressed in hypothalamus, hippocam-
pus and neurons [32,33]. GLP-1, liraglutide and other GLP-1
analogues cross the blood brain barrier [34–36] where they
specifically bind to GLP-1R to improve learning, memory and
exert neuroprotective effects [35,37]. Furthermore, enhanced
learning and memory was observed in wild-type mice with
increased expression of hippocampal GLP-1R [38] whereas GLP-
1R knockout animals showed learning deficiencies [32,38].
Previously, liraglutide has been shown to increase LTP [35,39–
41], reduce beta amyloid oligomers, plaque load, chronic
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inflammation and increase synaptic numbers in APP/PS1 mice
[35].
In this study, effects of acute and long-term systemic adminis-
tration of liraglutide on cell differentiation in wild type and APP/
PS1 mice at different ages were examined. We have previously
shown that liraglutide increases neural progenitor/stem cell
proliferation [42] and now investigate if cells survive and




Forty-eight APPSWE/PS1DE9 and Forty-eight wild type litter-
mate female mice aged 3, 6, 12, 15 were used in the experiment.
They were housed in single cages in a temperature controlled
holding room (21.5uC61) with 12:12 hour light and dark cycle.
Food and water were provided ad libitum. All experiments were
carried out in accordance with the UK animals (Scientific
Procedures) Act 1986.
2.2. Drug Treatment
Control group (n = 6) and liraglutide treated group (n = 6) were
injected intraperitonially once daily with 0.9% saline or 25 nmol/
kg body weight liraglutide (GL Biochem Ltd Shanghai) respec-
tively for 7 days (acute treatment) and 37 days (chronic treatment).
5-bromo-29-deoxyuridine (BrdU, 50 mg/kg i.p. Sigma, UK) is a
thymidine analogue, which binds to DNA during S-phase and is
used as cell proliferation marker was injected once daily for 7 days
with the drug or saline. Animals were culled after 30 days after last
BrdU injection.
2.3. Perfusion
All animals were transcardially perfused with ice-cold phosphate
buffer. Brains were then retrieved and was placed in ice cold 4%
paraformaldehyde. After 24 hours brains were transferred to 30%
sucrose overnight, snap frozen with EnvirofreezTM (Sigma, UK)
and 40 microns thick coronal sections were cut at anatomical
regions of 22 to 23 bregma [43] using Leica cryostat. The first
section was taken at random, then every 5th section afterwards
[44] was preserved in cryoprotect.
2.4. Immunohistochemistry
For BrdU and Doublecortin staining, endogenous peroxidase
activity was quenched by treating sections with 3% H2O2.
Sections were incubated in 0.3% Triton -100X and after washing
with PBS, DNA denaturation for BrdU staining was carried out by
incubating sections in 2N HCl at 37uC and then all sections were
blocked in 5% normal serum. Sections were then incubated in
monoclonal mouse anti BrdU (1:200, B8434, Sigma Aldrich, USA)
or goat polyclonal anti doublecortin (1:200, sc-8066, SantaCruz,
Germany) and incubated overnight at 4uC. Sections were then
washed with phosphate buffer saline and biotinylated secondary
antibody (1:200 anti mouse for BrdU or 1:500 anti goat for
Doublecortin) was added. This was followed by amplification with
Avidin-Biotin complex (Vectastain elite ABC kit PK-6102 and
PK-6105, Vector laboratories Ltd, Peterborough, UK) and
visualized using a detection kit (SK-4700, SG Substrate, Vector
laboratories Ltd, Peterborough, UK).
For Ki67 staining, sections were treated with 10 mM sodium
citrate buffer at 90uC for 30 minutes for antigen retrieval and after
incubating in 0.3% triton-100X, sections were blocked in 5%
serum and 5% BSA mixture and then incubated in rabbit
polyclonal anti Ki67 antibody (1:200, ab15580, Abcam, UK)
overnight at 4uC. Sections were then washed and incubated in
fluorescent secondary Alexa FluorH goat anti rabbit 488 antibody
(1:200, A11008, Invitrogen, UK) and mounted on slide.
2.5. Double Immunoflourescence
To determine the phenotype of newly generated cells double
Immunoflourescence was used. Tissue sections were permeabilized
in 0.3% Triton -100X, denatured in 2N HCl and after
neutralisation with 0.1M Borate buffer were blocked 5% goat
serum+ 5% BSA. Sections were then incubated overnight at 4uC
Figure 1. Quantification of BrdU positive cells in the SGZ of WT and APP/PS1 animals at different ages. Progenitor cell proliferation in
SGZ decreases with age. Values are expressed as mean 6 SEM (n= 6). ***p,0.001 compared with respective controls.
doi:10.1371/journal.pone.0058784.g001
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in mixture of primary antibodies of either monoclonal rat anti
BrdU (1:200, AB6326, Abcam, Cambridge, UK) and mouse
monoclonal anti NeuN (mature neuron marker, 1:200, MAB377,
Millipore, USA) or monoclonal mouse anti GFAP (astrocyte
marker, 1:500, MAB3402, Millipore) or polyclonal rabbit anti
Iba1 (microglia marker, 1:1000, 001-20001, Wako, Germany).
Sections were washed in PBS and incubated for 60 min at room
temperature in mixture of fluorescent secondary antibodies of goat
anti rat Alexa FluorH 555 (1:150, A21434, Invitrogen, UK) with
goat anti mouse Alexa FluorH 488 (1:150, A11001) goat anti rabbit
Alexa FluorH 488 (1:150 A11008, Invitrogen, UK). Sections were
mounted on silanized slides and cover-slipped using Vectashield
mounting medium (H1000, Vector Laboratories, Peterborough,
UK).
2.6. Quantification of Cells
Images of BrdU, Ki67, DCX-immunoreactive cells and double
immunofluorescent positive cells were taken from Axio Scope 1
(Carl Zeiss, Germany) equipped with digital camera (Axiocam,
Carl Zeiss) or fluorescent microscope (Olympus, BX-URA2). The
cells in all groups were counted in 7 sections/each animal. For
analysis, unbiased 2D stereology rules were applied, and cells were
counted using an unbiased dissector (one per section),
500 mmx500 mm in size. To ensure unbiased sectioning, the first
section of the hippocampus was taken at random, then every 5th
section afterwards [45]. The total cell count was obtained by
averaging the counts from the sections taken from each animal.
Figure 2. Quantification of BrdU positive cells in the SGZ. Acute treatment with liraglutide does not increase cell proliferation at any age in
wild type animals whereas in APP/PS1 animals treatment with liraglutide increases cell proliferation regardless of age. Quantification of Ki67 positive
cells in the SGZ. Acute treatment with liraglutide increases endogenous cell proliferation at all ages in wild type and APP/PS1 animals *p,0.05,
**p,0.01 compared with saline control. Values are expressed as mean 6 SEM (n= 6).
doi:10.1371/journal.pone.0058784.g002
Figure 3. Acute treatment with liraglutide significantly increases DCX-immunoreactive cells in the DG of both wild type and APP/
PS1 at all ages. *p,0.05, **p,0.01 compared with saline control. Values are expressed as mean 6 SEM (n= 6).
doi:10.1371/journal.pone.0058784.g003
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Figure 4. Quantification of BrdU positive cells in the SGZ. Chronic treatment with liraglutide increases cell proliferation in both wild type and
APP/PS1 animals regardless of age. Quantification of Ki67 immunoreactive cells in the SGZ. Chronic treatment with liraglutide increases endogenous
cell proliferation in both wild type and APP/PS1 animals regardless of age. *p,0.05, **p,0.01 compared with saline control. Values are expressed as
mean 6 SEM (n= 6).
doi:10.1371/journal.pone.0058784.g004
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2.7. Statistics
Student t test, One-way analysis of variance (ANOVA) and Two
way repeated measure ANOVA followed by Bonferroni’s post hoc
test were used for statistical analysis using Prism (Graph-Pad
PrismH, San Diego, CA). All values were expressed as mean 6
SEM. A p-value of ,0.05 was considered to be statistically
significant.
Results
3.1. Effect of Age on Cell Proliferation and Cell Survival in
WT and APP/PS1 Animals
A significant decrease in number of BrdU positive cells was
observed in both WT controls and APP/PS1 animals with
progression of age (Figure 1). Significant effect of age (F = 97.13,
df 3, p,0.001) and genotype (F= 69.14, df 1, p,0.001) was
observed on cell proliferation, and the interaction between ageing
and genotype was also significant (F = 17.89, df 3, p,0.001).
Bonferroni post hoc tests revealed a difference in BrdU numbers in
both WT and APP/PS1 mice from 3 to 6 months (t = 4.842,
p,0.001 and t = 3.199, p,0.001, respectively), and 6 to
12 months (t = 6.486, p,0.001 and t = 2.354, p,0.001). No
difference was seen between 12 to 15 months for both WT and
APP/PS1 (t = 1.022, p.0.05 and t = 0.4442, p.0.05, respective-
ly). Fewer BrdU positive cells were found in APP/PS1 mice
compared to WT littermates at 3 and 6 months of age (t = 8.130,
p,0.001 and t = 6.486, p,0.001). There was a non-significant
trend for lower number of BrdU cells at 12 and 15 months in
APP/PS1 mice compared to WT (t = 0.8885, p.0.05 and
t = 0.3110, p.0.05). See Figure 1.
3.2 Acute Liraglutide Treatment (for 7 Days, Once Daily
Ip.)
Cell Proliferation and Survival. Wild type mice treated
with liraglutide did not show any significant increase in the
number of newly generated cells in their dentate gyrus (BrdU
stain), compared to animals treated with saline in 3, 6, 12 and
15 months of age (p.0.05). Treatment of APPswe/PS1E9 animals
with liraglutide increases cell proliferation as compared to saline
control. The 3 month old group showed a 33% increase. The
6 month group showed an increase of 41% (p,0.05), the
12 month group showed an increase of 69% (p,0.01) and the
15-month group showed a 65% increase in positive cells as
compared to saline treated controls (p,0.05).
Increased cell proliferation as shown by Ki67 immunostaining
was observed in WT animals after acute treatment with liraglutide.
The 3 month old group showed 90% increase (p,0.01) in Ki67
cells in the DG compared to saline controls. The 6 months,
12 months and 15 months old WT animals showed 63%, 114%
and 137% increase (p,0.05) in immunoreactive Ki67 cells
respectively. Similarly, APP/PS1 animals of 3, 6, 12 and
15 months age showed 99%, 58%, 153% and 135% increase
(p,0.01 and p,0.05) in Ki67 positive cells compared to saline
treated groups respectively. See Figure 2.
Liraglutide Increases Neuroblast Differentiation in Both
WT and APP/PS1 Animals. Increased doublecortin positive
cells were observed in 3, 6, 12 and 15 months old WT mice
treated with liraglutide for 7 days by 59%, 26%, 57% and 61%
respectively compared to saline treated groups (p,0.05 and
p,0.01). Acute treatment of 3, 6, 12 and 15 months old APP/PS1
mice also showed increased DCX-immunoreactive cells by 50%,
33%, 53% and 72% respectively compared to control groups
(p,0.05). See Figure 3.
Liraglutide Does Not Increase Neurogenesis in APPswe/
PS1E9 and Wild Type Control. Double Immunostaining with
BrdU/NeuN staining was utilised to evaluate the differentiation of
progenitor cells to mature neuron. In acutely treated wild type
animals, percentage difference of BrdU/NeuN co-labelled cells in
drug group compared to saline control for 3-month was 8%
(p.0.05), for 6-month was 21% (p.0.05), for 12-months was 20%
(p.0.05) and for 15-month was 22% (p.0.05), no result was
statistically significant. In AD mice, a non-significant trend was
observed in where 3-month group showed 19% increase (p.0.05),
for the 6 month group it was 18% (p.0.05), for the 12 month it
was 21% (p.0.05) and for 15-month was 12% (p.0.05).
Gliogenesis in the Mouse Brain. Not all newly generated
cells expressed the NeuN antigen, indicating they differentiated
into other phenotypes like glia cells. Double immunostaining
showed a very low percentage of newly expressed astrocytes and
microglia in the dentate, and no difference was seen between
groups. In Wild type animals that were acutely treated with
liraglutide, the average percentage of newly produced GFAP and
microglia cells were 5.6863.15 and 6.362.65 respectively
compared to 6.8561.70 and 6.4861.74 (p.0.05) in saline control
animals. The percentages for GFAP and Iba1 was 7.363.3 and
7.5561.47 respectively compared to 9.762.4 and 10.0761.45 of
those of saline controls which was not significant (p.0.05).
3.3. Chronically treated mice (37 days of injection once-
daily ip.)
Liraglutide Increases Cell Proliferation and Survival in
Wild Type Mice. All four age groups of wild type mice showed
a significant increase in the number of BrdU positive cells in the
DG as compare to saline controls. There was an increase of 20%,
(p = 0.0457), 22%, (p = 0.0467), 36% (p= 0.0455) and 52%
(p,0.05) of BrdU positive cell in mice group aged 3, 6, 12 and
15 months respectively. Drug treatment of APPswe/PS1E9 animals
with liraglutide increases cell proliferation (BrdU stain) as
compared to saline control. The 3 month old group showed a
55% increase (p,0.01). The 6 month group showed an increase of
50% (p,0.05), the 12 month group showed an increase of 68%
(p,0.01) and the 15-month group showed a 79% increase in
positive cells as compared to saline treated controls (p,0.01). See
Figure 4.
When analysing Ki67 positive cells, liraglutide increased cell
proliferation in 3, 6, 12 and 15 months old WT mice by 94%,
103%, 143% and 122% respectively when compared to saline
treated group (p,0.05). Similarly, 3, 6, 12, and 15 months old
APP/PS1 mice group also showed increased levels of Ki67
immunostaining by 175%, 70% 215% and 120% respectively
compared to saline groups (p,0.01). See Figure 4.
Chronic Administration of Liraglutide Increases
Neuroblast Differentiation in Both WT and APP/PS1
Animals. Chronic treatment with liraglutide increased the
numbers of immature neurons (DCX stain) in 3, 6, 12 and
15 months in WT mice by 43%, 40%, 74% and 68% respectively
compared to control groups (p,0.05 and p,0.01). Similarly,
increased levels of DCX positive cells in 3, 6, 12 and 15 months
APP/PS1 animals by 35%, 48%, 88% and 94% respectively
compared to saline groups (p,0.05 and p,0.01). See Figure 5.
Liraglutide Treatment Increases Neuronal
Differentiation. The numbers of BrdU+NeuN (double stain-
ing) positive cells in WT and APP/PS1 animals treated with
liraglutide compared to saline group are shown in Figure 6. In
both wild type littermate and APP/PS1 mice, chronic treatment
with liraglutide showed an increase in neuronal numbers
compared to saline controls. The Wild type and APP/PS1 6-
Liraglutide Increases Stem Cell Differentiation
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month group showed an increase of 57% (p,0.05) and 50%
(p,0.05) of new neurons compared to saline control. For 12-
months, the difference was 41% (p,0.05) and 70% (p,0.01), and
for the 15-month group the difference was 72% (p,0.05) and 77%
(p,0.05) respectively. No difference was seen in the 3-month old
groups for both wild type (p.0.05) and APP/PS1 (p.0.05)
animals (Figure 6).
Gliogenesis. Not all newly generated cells expressed the
NeuN antigen, indicating they differentiated into other phenotypes
like glia cells. Double immunostaining showed a very low
percentage of newly expressed astrocytes and microglia in the
dentate, and no difference was seen between groups. In chronically
treated animals, the average percentage was 6.2861.20 and
3.5861.60 compared to 4.9561.07 and 4.7561.80 (p.0.05)
respectively. In APP/PS1 animals the average percentage of
GFAP and Iba1 was higher compared to wild type. The values for
GFAP and Iba1 was 6.8561.75 and 5.7062.55 respectively
compared to 8.8562.0 and 9.3862.65 of those of saline group,
which was not significant (p.0.05). See Figure 6.
Discussion
Generation of new progenitor cells and their differentiation into
neurons in the dentate gyrus takes place throughout the life of
rodents and humans [3,11,42]. The new neurons have shown to
extend their axonal projections into the hippocampal CA3 area
[46], indicating that they play a functional role in the neuronal
network of the hippocampus.
There is an age-dependent decline in the number of immuno-
reactive BrdU cells, a marker of proliferating cells, in the SGZ of
the dentate gyrus in both wild type and APP/PS1 animals. This
decrease in neurogenesis with age has been reported previously on
rodents and humans [10,11,42]. Significantly, APP/PS1 mice
showed consistently lower numbers of newly generated cells in
their DG compared to aged matched wild type littermates when
compared at ages 3 months and 6 months, while at 12 and
15 months no difference was seen. This may be due to AD
pathology impairing the proliferation of NSC at earlier stages of
the life in the AD mouse model, which has been described
previously in several studies with various mouse models of AD
[19,42,47]. Also, as the numbers of new neurons were already very
low in the older groups, a significant reduction in numbers would
be hard to achieve.
The important roles of various factors such as exercise, enriched
environment, trauma and growth factors on the regulation of
neurogenesis have been studied in detail [1] [48,49]. Growth
factors such as epidermal growth factor (EGF), fibroblast growth
factor-2 (FGF-2) and glia cell line-derived neurotrophic factor
(GDNF) when administered intracerebroventricular (i.c.v.) in rats
with ischemic brain injury, increased neurogenesis was observed,
Figure 5. Chronic treatment with liraglutide increases neuroblast differentiation in both wild type and APP/PS1 animals regardless
of age. *p,0.05, **p,0.01 compared with saline control. Values are expressed as mean 6 SEM (n = 6).
doi:10.1371/journal.pone.0058784.g005
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and the new neurons were shown to integrate functionally into the
network [50,51]. The roles of NGF and BDNF in neurogenesis
also has been researched in some detail, and their potential use as
a treatment for neurodegenerative disease has been investigated
[17,52–54]. Thus, compounds that can selectively promote
proliferation of NSC and prompt their differentiation to neuronal
phenotype may be of use as a treatment of neurodegenerative
diseases such as AD [16].
We observed that a 1-week treatment of wild type animals with
liraglutide had no effect on BrdU positive cell numbers, but
showed increased endogenous cell proliferation as shown by Ki67
immunoreactive positive cells at 3, 6, 12 or 15 months of age. In
contrast, APP/PS1 animals treated acutely for 7 days with
liraglutide showed a significant increase in BrdU and Ki67
positive cells at ages 3, 6, 12 and 15 months. Amyloid deposition is
related to decreased neurogenesis in AD mice. APP/PS1 double
transgenic mice develop early-onset amyloidosis, as young as
3 months, with plaque deposits by 5–6 months, progressing with
age up to 15 months [42,55]. Beta-amyloid oligomers have been
shown to interfere with insulin signaling [56], and since insulin is
an important growth factor that also activates stem cells, this
impairment in insulin signaling may be a reason for the
impairment of stem cell proliferation found in the APP/PS1 mice
[57,58]. A second reason for the normalisation of neurogenesis by
liraglutide may be the fact that the chronic inflammation response
was reduced. Cytokines released during a chronic inflammation
response reduced stem cell proliferation [21]. We have previously
shown that liraglutide reduces the chronic inflammation response
in this APP/PS1 mouse strain [35]. This would explain why there
was little effect on neuronal progenitor proliferation in wild type
mice as there were no plaques nor the associated chronic
inflammation response. The effects of acute treatment by
liraglutide on cell proliferation in-vivo in AD mice has not been
studied previously.
The effects of long-term administration of liraglutide on
progenitor cell proliferation in the SGZ of dentate gyrus was
examined in APP/PS1 and WT littermates. The 37- day
treatment with liraglutide significantly increased the number of
immunopositive BrdU cells and also Ki67 positive cells in 3, 6, 12
and 15-months in both APP/PS1 and WT animals compared to
saline controls. Previous studies showed that GLP-1 and analogues
of GLP-1 induce cell proliferation in vivo and in vitro [9,59–61].
GLP-1 receptors are expressed all throughout the brain especially
on neurons in the hippocampus and cortex [33,62]. Furthermore,
GLP-1 also functions as a growth factor, has neuroprotective
characteristics and enhances cell survival [22,63]. GLP-1R
mediated activation of mitogen activated protein kinase (MAPK)
is crucial for hippocampal neurogenesis [38], which is associated
with hippocampal-dependent learning and memory [64,65].
Differentiation capacity of NSC on acute treatment with
liraglutide showed no changes in both WT and APP/PS1 mice
at any age. There was no difference in the percentage of newly
generated cells expressing mature marker (NeuN) of neurons
compared to control group. No difference in neuronal phenotype
number was seen in 3-month old WT and APP/PS1 group treated
chronically with liraglutide. Interestingly, in chronic treatment
Figure 6. Chronic treatment with liraglutide significantly increases differentiation of newly produced cells to new neurons in wild
type group at 6, 12 and 15 months wild type mice and APP/PS1 mice. No difference was seen at 3 months of age. No significant difference
was seen in newly generated glia cell. *p,0.05, **p,0.01 compared with saline control. Values are expressed as mean 6 SEM (n= 6).
doi:10.1371/journal.pone.0058784.g006
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with liraglutide, both APP/PS1 and WT littermates showed
significant increase in number of cells incorporating BrdU and
mature neuronal marker NeuN at 6, 12 and 15 months, indicating
increased neuroblast differentiation. Interestingly, both acute and
chronic treatment increased neuroblast differentiation in WT and
APP/PS1 animals. This suggest acute requirement of liraglutide is
sufficient for its trophic properties in neuroblast differentiation but
chronic administration is essential for full differentiation into
mature neurons.
Not all newly generated cells differentiate into neuron, but some
transform into glial phenotype. Liraglutide did not appear to affect
the differentiation into glial. There was a trend towards a decrease
the number of new cells transforming to glia cells, which was not
significant and may be explained by an increase in cells
differentiating into neurons. Previous studies have shown that
liraglutide significantly decreases activated microglia and activated
astrocytes in APP/PS1 mouse brains and WT mouse brains [35],
but no research has been conducted previously on effects of
incretins on differentiation of NSC into glial phenotypes. The
results shown here suggest a chronic requirement of liraglutide to
activate the differentiation process of NSC into neurons. However,
our study does not rule out that an increased survival of NSC that
may contribute to net neurogenic potential of liraglutide. Past
studies have shown an increase in neuronal markers (MAP2, b-III-
tubulin) in cell cultures and an increase in DCX positive cells in
SVZ of rat brain after chronic exendin-4 treatment [9,60].
Additionally, GLP-1 promotes beta cell proliferation [61] and
differentiation from embryonic stem cells [66]. The mechanism of
action of liraglutide in differentiation could be exerted via
upregulation of Mash1 (involved in neuronal differentiation in
hippocampus) [67].
This is the first study that investigated the proliferation and
differentiation properties of GLP-1 analogue, liraglutide in wild
type and APP/PS1 animals at different ages. We are also first to
look at the effects of acute and chronic treatment with liraglutide
on progenitor cell proliferation and differentiation at different ages
of wild type and animals with AD pathology.
Based on findings of our study and previous work that showed
liraglutide improves cell proliferation in SGZ, increases differen-
tiation of progenitor cells to neurons, this drug and other GLP-1
analogues have therapeutic potential to treat neurodegenerative
disorders such as Alzheimer’s and Parkinson’s disease.
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